Monopar Therapeutics (MNPR) Retained Earnings (2016 - 2025)
Monopar Therapeutics (MNPR) reported Retained Earnings of -$89.5 million for Q4 2025, down 248766.37% on a YoY basis from N/an in Q4 2024, and down 6.16% sequentially from -$84.3 million in Q3 2025.
Monopar Therapeutics (MNPR) Retained Earnings (2016 - 2025) Analysis & Trends
Monopar Therapeutics (MNPR) has 10 years of Retained Earnings data on file, last reported at -$89.5 million in Q4 2025.
- For the quarter ending Q4 2025, Retained Earnings fell 248766.37% year-over-year to -$89.5 million; the trailing twelve-month figure through Dec 2025 stood at -$89.5 million (down 248766.37% YoY), and the FY2025 full-year result was -$89.5 million, down 248766.37% from the prior year.
- Retained Earnings declined to -$89.5 million in Q4 2025, from -$84.3 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $60.7 million in Q1 2022 to a low of -$89.5 million in Q4 2025.
- A 5-year average of -$28.0 million and a median of -$18.1 million in 2021 frame the typical range for Retained Earnings.
- Peak annual rise in Retained Earnings reached 1190591.06% in 2022, while the deepest fall reached 1639267.75% in 2022.
- Tracing MNPR's Retained Earnings over 5 years: stood at -$3160.0 in 2021, then plunged by 1639267.75% to -$51.8 million in 2022, then jumped by 99.97% to -$14132.0 in 2023, then soared by 354.68% to $35992.0 in 2024, then tumbled by 248766.37% to -$89.5 million in 2025.
- Business Quant data shows MNPR's Retained Earnings at -$89.5 million in Q4 2025, -$84.3 million in Q3 2025, and $77577.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Monopar Therapeutics | 707.36 Mn | 645.53 Mn | - | -89.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -89.50 Mn |
| Sep 30, 2025 | -84.31 Mn |
| Jun 30, 2025 | 77,577.00 |
| Mar 31, 2025 | -78.42 Mn |
| Dec 31, 2024 | 35,992.00 |
| Sep 30, 2024 | -10,991.00 |
| Jun 30, 2024 | 8,258.00 |
| Mar 31, 2024 | -61.80 Mn |
| Dec 31, 2023 | -14,132.00 |
| Sep 30, 2023 | -58.40 Mn |
| Jun 30, 2023 | -56.40 Mn |
| Mar 31, 2023 | -54.24 Mn |
| Dec 31, 2022 | -51.80 Mn |
| Sep 30, 2022 | -48.91 Mn |
| Jun 30, 2022 | 17,466.00 |
| Mar 31, 2022 | 60.70 Mn |
| Dec 31, 2021 | -3,160.00 |
| Sep 30, 2021 | -5,147.00 |
| Jun 30, 2021 | -36.15 Mn |
| Mar 31, 2021 | -5,099.00 |